Publications by authors named "Lena van der Wekken-Pas"
Article Synopsis
- - The review focuses on recent findings over the last two years regarding how antiretroviral drugs behave in pregnant women, including their effects on placental transfer and exposure through breastmilk.
- - It highlights key developments like the FDA's label change for Bictegravir due to its decreased yet adequate concentration during pregnancy, as well as findings from studies on long-acting formulations like cabotegravir and rilpivirine.
- - The overall conclusion emphasizes the need for better drug data during pregnancy and lactation, suggesting that more research and incentives are necessary to ensure women receive accurate information about their medications early in the drug development process.
This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred.
View Article and Find Full Text PDFArticle Synopsis
- Both dolutegravir and efavirenz are effective treatments for preventing HIV transmission during pregnancy but may cause neuropsychiatric symptoms, which need further investigation in this population.
- A secondary analysis of the DolPHIN2 study assessed depression, anxiety, and sleep quality in 268 women who received either treatment late in pregnancy, showing notable rates of depression but no differences between the drug regimens.
- Findings indicate high initial depression scores that decreased over time, emphasizing the importance of psychological support for women diagnosed with HIV during pregnancy.
Background: Cytomegalovirus causes morbidity and mortality, especially in immunocompromised patients, and is treated with (val)ganciclovir. Therapeutic drug monitoring of ganciclovir is often performed; however, clinically established target trough levels corresponding to efficacy are lacking. In 2021, our clinic increased the target trough level for ganciclovir from 1 to 2 mg/L to 2-4 mg/L.
View Article and Find Full Text PDF